Published in Medical Verdicts and Law Weekly, May 31st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Medtronic, Inc.
Report 1: Two-year results from the Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positive clinical profile of the Endeavor(R) drug-eluting coronary stent and bring to nearly 1,300 the number of Endeavor patients who have at least two years of follow-up. Significantly, among those 1,300 Endeavor patients, there have been no reported cases of late stent thrombosis using the independent, pre-specified clinical trial protocol definitions for thrombosis. The results were presented today...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.